Tao, Yong
Lamas, Veronica
Du, Wan
Zhu, Wenliang
Li, Yiran
Whittaker, Madelynn N. http://orcid.org/0000-0002-3382-1134
Zuris, John A.
Thompson, David B.
Rameshbabu, Arun Prabhu http://orcid.org/0000-0001-8599-569X
Shu, Yilai http://orcid.org/0000-0001-8893-434X
Gao, Xue http://orcid.org/0000-0003-3213-9704
Hu, Johnny H.
Pei, Charles
Kong, Wei-Jia http://orcid.org/0000-0001-5410-2297
Liu, Xuezhong
Wu, Hao
Kleinstiver, Benjamin P. http://orcid.org/0000-0002-5469-0655
Liu, David R.
Chen, Zheng-Yi http://orcid.org/0000-0002-1452-4193
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R35GM118062, RM1HG009490)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute
Howard Hughes Medical Institute
Article History
Received: 7 July 2022
Accepted: 31 July 2023
First Online: 15 August 2023
Competing interests
: Z.-Y.C. is a cofounder of Salubritas Therapeutics. He and D.R.L. have filed patent applications on: Efficient delivery of therapeutic molecules in vitro and in vivo” (15/523325) and “Method for efficient delivery of therapeutic molecules in vitro and in vivo” (15/523321). B.P.K. is an inventor on patents and patent applications filed by Mass General Brigham that describe genome engineering technologies. B.P.K. is a consultant for Avectas Inc., EcoR1 capital, and ElevateBio, and is an advisor to Acrigen Biosciences and Life Edit Therapeutics. X.L. is a SAB member of Rescue Hearing Inc, and a SAB member of Salubritas Therapeutics. The other authors declare no competing interests.